The FDA has approved Dupixent (dupilumab) for treating chronic spontaneous urticaria (CSU) in children aged 2 to 11 who remain symptomatic despite antihistamine treatment. This approval expands existing indications for older patients and is based on clinical trial data showing significant symptom reduction. Dupixent targets key inflammatory pathways, offering a new option for young children with limited alternatives. The drug is already approved for CSU in children in the EU and other countries, with ongoing studies for additional inflammatory conditions.
The global blood glucose monitoring system market, valued at $16.8 billion in 2025, is projected to grow to $39.4 billion by 2035 at an 8.9% CAGR. Growth is fueled by rising diabetes prevalence, advancements in AI-enabled monitoring devices, and incr...
Paulo Fontoura has resigned from the Board of Directors at Lakefront Biotherapeutics following his appointment as Executive Vice President and Global Head of Research & Development Pharma at Sanofi. Lakefront's board chair congratulated Fontoura and ...
